AUSTIN, Texas, Nov. 16, 2021 /PRNewswire/ -- Aeglea
BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage
biotechnology company developing a new generation of human enzyme
therapeutics as innovative solutions for rare metabolic diseases,
today announced the appointment of Hunter
C. Smith to its board of directors. Mr. Smith currently
serves as the chief financial officer of Rhythm
Pharmaceuticals.
"We are excited to welcome Hunter to our board of directors and
to the Aeglea family," said Anthony
Quinn, M.B Ch.B, Ph.D., president and chief executive
officer of Aeglea. "Hunter brings a wealth of experience as a
biotech leader including corporate strategy, global commercial
planning and product launches. His addition to our board will bring
valuable experience and input as we further our mission to bring
human enzyme therapies to people living with rare metabolic
diseases."
"I'm excited to be joining the board of Aeglea, particularly as
the company is on the cusp of pivotal data from its trial for its
Arginase 1 Deficiency program next month," said Mr. Smith. "I look
forward to working with existing board members and the Aeglea team
as they advance Aeglea toward becoming a commercial-stage company
while continuing to realize the immense potential of its human
enzyme therapy pipeline."
Mr. Smith's roles at biopharma companies include senior-level
leadership, corporate strategy and financial oversight of
commercial operations. Mr. Smith has served as the chief financial
officer of Rhythm Pharmaceuticals since 2017 and served as interim
chief executive officer from March to July
2020. Prior to joining Rhythm, Mr. Smith was vice president,
finance and chief financial officer of Celgene Corporation's
inflammation and immunology business unit where he provided
financial and strategic leadership for the global launch of
Otezla®. Prior to Celgene, Mr. Smith held roles of increasing
responsibility at Bunge Limited. He holds an M.B.A in finance from
NYU's Stern School of Business and a
B.A. in history, with honors, from Northwestern University.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is
a clinical-stage biotechnology company redefining the potential of
human enzyme therapeutics to benefit people with rare metabolic
diseases with limited treatment options. Aeglea's lead product
candidate, pegzilarginase, is in a pivotal Phase 3 trial for the
treatment of Arginase 1 Deficiency and has received both Rare
Pediatric Disease and Breakthrough Therapy Designations. The
company began dosing patients in a Phase 1/2 clinical trial of
AGLE-177 for the treatment of Homocystinuria in June 2021. AGLE-177 has also been granted Rare
Pediatric Disease Designation. Aeglea has an active discovery
platform focused on engineering small changes in human enzymes to
have a big impact on the lives of patients and their families. For
more information, please visit http://aeglea.com.
Safe Harbor / Forward Looking Statements
This press
release contains "forward-looking" statements within the meaning of
the safe harbor provisions of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as: "anticipate," "intend," "plan,"
"goal," "seek," "believe," "project," "estimate," "expect,"
"strategy," "future," "likely," "may," "should," "will" and similar
references to future periods. These statements are subject to
numerous risks and uncertainties that could cause actual results to
differ materially from what we expect. Examples of forward-looking
statements include, among others, statements we make regarding our
ability to obtain regulatory approval for, and commercialize,
pegzilarginase, recognize milestone and royalty payments from our
agreement with Immedica, cash forecasts, the timing and success of
our clinical trials and related data, the timing and expectations
for regulatory submissions and approvals, timing and results of
meetings with regulators, the timing of announcements and updates
relating to our clinical trials and related data, our ability to
enroll patients into our clinical trials, the expected impact of
the COVID-19 pandemic on our operations and clinical trials,
success in our collaborations, the potential addressable markets of
our product candidates and the potential therapeutic benefits and
economic value of our lead product candidate or other product
candidates. Further information on potential risk factors that
could affect our business and its financial results are detailed in
our most recent Annual Report on Form 10-Q for the quarter ended
September 30, 2021 filed with the
Securities and Exchange Commission (SEC), and other reports as
filed with the SEC. We undertake no obligation to publicly update
any forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-appoints-hunter-c-smith-to-board-of-directors-301424622.html
SOURCE Aeglea BioTherapeutics, Inc.